Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3952-3957

  Guan, Yongjun ^a   Sajadi, Mohammad M ^a   Kamin Lewis, Roberta ^a   Fouts, Timothy R ^b   Dimitrov, Anthony ^b   Zhang, Zhixin ^c   Redfield, Robert R ^a   DeVico, Anthony L ^a   Gallo, Robert C ^a   Lewis, George K ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Profectus BioSciences Inc   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

CD4bs antibody; CD4i antibody; Elite controller; Human monoclonal antibody; Natural viral suppressors

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIBODY; CD4BS ANTIBODY; CD4I ANTIBODY; CHEMOKINE RECEPTOR CCR5; EPITOPE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR BINDING; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VOLUNTEER;

ANTIBODY FORMATION; ANTIGENS, CD4; B-LYMPHOCYTES; CONSERVED SEQUENCE; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; TISSUE DONORS; TITRIMETRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62649166814     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813392106     Document Type: Article

References (40)

1. Gallo RC (2005) The end or the beginning of the drive to an HIV-preventive vaccine: A view from over 20 years. Lancet 366:1894-1898.
2. Fauci AS, et al. (2008) HIV vaccine research: The way forward. Science 321:530-532.
3. Braibant M, et al. (2006) Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: Prevalence and association with neutralizing activity. AIDS 20:1923-1930.
4. Walker BD (2007) Elite control of HIV infection: Implications for vaccines and treatment. Top HIV Med 15:134-136.
5. Sajadi MM, Heredia A, Le N, Constantine NT, Redfield RR (2007) HIV-1 natural viral suppressors: Control of viral replication in the absence of therapy. AIDS 21:517-519.
6. Sajadi MM, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J AIDS, in press.
7. Li Y, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13:1032-1034.
8. Dhillon AK, et al. (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 81:6548-6562.
9. Wei X, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422:307-312.
10. Bailey JR, et al. (2006) Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80:4758-4770.
11. Pereyra F, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571.
12. Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.
13. Crotty S, et al. (2003) Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969-4973.
14. Jilg W, Schmidt M, Deinhardt F (1990) Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 335:173-174.
15. Banatvala J, Van Damme P, Oehen S (2000) Lifelong protection against hepatitis B: The role of vaccine immunogenicity in immune memory. Vaccine 19:877-885.
16. Bauer T, Jilg W (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24:572-577.
17. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ (1997) Protection provided by hepatitis B vaccine in a Yupik Eskimo population-Results of a 10-year study. J Infect Dis 175:674-677.
18. West DJ, Calandra GB (1996) Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 14:1019-1027.
19. Moir S, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205:1797-1805.
20. Titanji K, et al. (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108:1580-1587.
21. Decker JM, et al. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1407-1419.
22. Kwong PD, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
23. Rizzuto CD, et al. (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
24. Wyatt R, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
25. Robinson JE, Elliott DH, Martin EA, Micken K, Rosenberg ES (2005) High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. Hum Antibodies 14:115-121.
26. Burton DR, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
27. Traggiai E, et al. (2004) An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med 10:871-875.
28. Huang CC, et al. (2004) Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 101:2706-2711.
29. DeVico A, et al. (2007) Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 104:17477-17482.
30. Gray ES, et al. (2007) Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81:6187-6196.
31. Fouts TR, et al. (2000) Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 74:11427-11436.
32. Center RJ, Lebowitz J, Leapman RD, Moss B (2004) Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 78:2265-2276.
33. Vu JR, et al. (2006) An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro. AIDS Res Hum Retroviruses 22:477-490.
34. Zhang MY, et al. (2004) Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 78:9233-9242.
35. Moore JP, Wallace LA, Follett EA, McKeating JA (1989) An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 3:155-163.
36. Turbica I, Posner M, Bruck C, Barin F (1995) Simple enzyme immunoassay for titration of antibodies to the CD4-binding site of human immunodeficiency virus type 1 gp120. J Clin Microbiol 33:3319-3323.
37. Fouts T, et al. (2002) Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 99:11842-11847.
38. Li M, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108-10125.
39. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903-1915.
40. Tiller T, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329:112-124.